Ginkgo Biloba extract: review and assessment of health benefits and potential side effects
DOI:
https://doi.org/10.12775/JEHS.2025.80.59960Keywords
ginkgo biloba, ginkgo biloba extract, GBE, EGb 761Abstract
Introduction
Ginkgo biloba (L.) is used in pharmacotherapy as an extract rich in bioactive compounds, which is obtained from its leaves. The improvement of age-associated cognitive decline and quality of life in mild dementia is a well-established use of Ginkgo Biloba extract (GBE) medicines. In Europe, it is also used as complementary therapy for Alzheimer’s disease and cardiovascular disorders. Its use also shows promising research outcomes for potential future indications, including in the treatment of tinnitus, age-related macular degeneration, and the prevention of high-altitude cerebral edema.
Aim of the Study
The aim of the study is to present recent findings on Ginkgo biloba extract medicines used in modern pharmacotherapy and its potential side effects, which should be considered during the treatment tailoring process.
Materials and methods
A thorough literature search was conducted in electronic databases, including PubMed, Google Scholar and ScienceDirect for relevant articles. The search terms included "Ginkgo Biloba", "Ginkgo Biloba extract”, “GBE", " EGb 761". All retrieved studies were screened for relevance based on their titles, abstracts, and full texts.
Conclusion
Ginkgo biloba extract is commonly used in the management of neurodegenerative diseases in Europe. Moreover, the latest reports indicate that it also has promising effects in the treatment of several conditions of different origins. Pharmaceuticals containing GBE may interact with a variety of medications, in formulations with inadequate quality control or exceeding the recommended therapeutic dose. However, when appropriately integrated into a well-managed pharmacotherapy regimen, they have the potential to positively influence patient health outcomes, thereby enhancing overall therapeutic effects.
Search
Gingko biloba, Ginkgo biloba extract, GBE, EGb 761
References
[1] E. Medicines Agency, “Adoption by Committee on Herbal Medicinal Products (HMPC) for,” 2015. [Online]. Available: www.ema.europa.eu/contact
[2] S. K. Singh, S. Srivastav, R. J. Castellani, G. Plascencia-Villa, and G. Perry, “Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders,” Neurotherapeutics, vol. 16, no. 3, pp. 666–674, Jul. 2019, doi: 10.1007/S13311-019-00767-8.
[3] M. S. Tan et al., “Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis,” J Alzheimers Dis, vol. 43, no. 2, pp. 589–603, 2015, doi: 10.3233/JAD-140837.
[4] “Adulteration of Ginkgo biloba Leaf Extract.” [Online]. Available: www.botanicaladulterants.org
[5] B. S. P. H. J.-Gertz and B. S. P. M. Kiefer, “Review About Ginkgo Biloba Special Extract EGb 761 (Ginkgo),” Curr Pharm Des, vol. 10, no. 3, pp. 261–264, Jan. 2004, doi: 10.2174/1381612043386437.
[6] M. Unger, “Pharmacokinetic drug interactions involving Ginkgo biloba,” Drug Metab Rev, vol. 45, no. 3, pp. 353–385, Aug. 2013, doi: 10.3109/03602532.2013.815200.
[7] B. S. P. H. J.-Gertz and B. S. P. M. Kiefer, “Review about Ginkgo biloba special extract EGb 761 (Ginkgo),” Curr Pharm Des, vol. 10, no. 3, pp. 261–264, Mar. 2004, doi: 10.2174/1381612043386437.
[8] K. S. Bhullar and H. P. V. Rupasinghe, “Polyphenols: Multipotent Therapeutic Agents in Neurodegenerative Diseases,” Oxid Med Cell Longev, vol. 2013, no. 1, p. 891748, Jan. 2013, doi: 10.1155/2013/891748.
[9] D. E. Barnes and K. Yaffe, “The projected effect of risk factor reduction on Alzheimer’s disease prevalence,” Lancet Neurol, vol. 10, no. 9, pp. 819–828, Sep. 2011, doi: 10.1016/S1474-4422(11)70072-2.
[10] I. J. Deary et al., “Age-associated cognitive decline,” Br Med Bull, vol. 92, no. 1, pp. 135–152, Dec. 2009, doi: 10.1093/BMB/LDP033.
[11] A. Konar, P. Singh, and M. K. Thakur, “Age-associated Cognitive Decline: Insights into Molecular Switches and Recovery Avenues,” Aging Dis, vol. 7, no. 2, p. 121, 2016, doi: 10.14336/AD.2015.1004.
[12] C. G. Lyketsos, O. Lopez, B. Jones, A. L. Fitzpatrick, J. Breitner, and S. Dekosky, “Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study,” JAMA, vol. 288, no. 12, pp. 1475–1483, Sep. 2002, doi: 10.1001/JAMA.288.12.1475.
[13] R. Ihl et al., “Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial,” Int J Geriatr Psychiatry, vol. 26, no. 11, pp. 1186–1194, Nov. 2011, doi: 10.1002/GPS.2662.
[14] O. Băjenaru et al., “Effectiveness and Safety Profile of Ginkgo biloba Standardized Extract (EGb761®) in Patients with Amnestic Mild Cognitive Impairment,” CNS Neurol Disord Drug Targets, vol. 20, no. 4, pp. 378–384, Feb. 2021, doi: 10.2174/1871527320666210208125524.
[15] S. I. Gavrilova, U. W. Preuss, J. W. M. Wong, R. Hoerr, R. Kaschel, and N. Bachinskaya, “Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial,” Int J Geriatr Psychiatry, vol. 29, no. 10, pp. 1087–1095, Oct. 2014, doi: 10.1002/GPS.4103.
[16] Y. Luo et al., “Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761,” Proc Natl Acad Sci U S A, vol. 99, no. 19, pp. 12197–12202, Sep. 2002, doi: 10.1073/PNAS.182425199.
[17] Z. X. Yao, Z. Han, K. Drieu, and V. Papadopoulos, “Ginkgo biloba extract (Egb 761) inhibits beta-amyloid production by lowering free cholesterol levels,” J Nutr Biochem, vol. 15, no. 12, pp. 749–756, Dec. 2004, doi: 10.1016/J.JNUTBIO.2004.06.008.
[18] S. Bastianetto, C. Ramassamy, S. Doré, Y. Christen, J. Poirier, and R. Quirion, “The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid,” Eur J Neurosci, vol. 12, no. 6, pp. 1882–1890, 2000, doi: 10.1046/J.1460-9568.2000.00069.X.
[19] C. Shi et al., “Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against beta-amyloid peptide-induced toxicity in SH-SY5Y cells,” Chem Biol Interact, vol. 181, no. 1, pp. 115–123, Sep. 2009, doi: 10.1016/J.CBI.2009.05.010.
[20] M. Canevelli, N. Adali, E. Kelaiditi, C. Cantet, P. J. Ousset, and M. Cesari, “Effects of Gingko biloba supplementation in Alzheimer’s disease patients receiving cholinesterase inhibitors: data from the ICTUS study,” Phytomedicine, vol. 21, no. 6, pp. 888–892, May 2014, doi: 10.1016/J.PHYMED.2014.01.003.
[21] M. Sereda, J. Xia, P. Scutt, M. P. Hilton, A. El Refaie, and D. J. Hoare, “Ginkgo biloba for tinnitus,” Cochrane Database Syst Rev, vol. 2022, no. 11, p. CD013514, Nov. 2022, doi: 10.1002/14651858.CD013514.PUB2.
[22] W. Wang, K. Ma, J. Liu, and F. Li, “Ginkgo biloba extract may alleviate viral myocarditis by suppression of S100A4 and MMP-3,” J Med Virol, vol. 91, no. 12, pp. 2083–2092, Dec. 2019, doi: 10.1002/JMV.25558.
[23] X. J. Chen, S. M. Ren, J. Z. Dong, C. G. Qiu, Y. W. Chen, and H. L. Tao, “Ginkgo biloba extract-761 protects myocardium by regulating Akt/Nrf2 signal pathway,” Drug Des Devel Ther, vol. 13, pp. 647–655, 2019, doi: 10.2147/DDDT.S191537.
[24] J. Wójcicki et al., “Ginkgo biloba extract inhibits the development of experimental atherosclerosis in rabbits,” Phytomedicine, vol. 1, no. 1, pp. 33–38, 1994, doi: 10.1016/S0944-7113(11)80020-6.
[25] J. Z. Chen, X. X. Wang, J. H. Zhu, Y. P. Shang, X. G. Guo, and J. Sun, “Effects of Ginkgo biloba extract on number and activity of endothelial progenitor cells from peripheral blood,” J Cardiovasc Pharmacol, vol. 43, no. 3, pp. 347–352, Mar. 2004, doi: 10.1097/00005344-200403000-00004.
[26] H. Silva and F. G. Martins, “Cardiovascular Activity of Ginkgo biloba—An Insight from Healthy Subjects,” Biology (Basel), vol. 12, no. 1, p. 15, Jan. 2022, doi: 10.3390/BIOLOGY12010015.
[27] M. P. Hilton, E. F. Zimmermann, and W. T. Hunt, “Ginkgo biloba for tinnitus,” Cochrane Database Syst Rev, vol. 2013, no. 3, Mar. 2013, doi: 10.1002/14651858.CD003852.PUB3.
[28] S. K. Swain, S. Nayak, J. R. Ravan, and M. C. Sahu, “Tinnitus and its current treatment–Still an enigma in medicine,” Journal of the Formosan Medical Association, vol. 115, no. 3, pp. 139–144, Mar. 2016, doi: 10.1016/J.JFMA.2015.11.011.
[29] O. Napryeyenko, G. Sonnik, and I. Tartakovsky, “Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial,” J Neurol Sci, vol. 283, no. 1–2, pp. 224–229, Aug. 2009, doi: 10.1016/J.JNS.2009.02.353.
[30] C. Imray, A. Wright, A. Subudhi, and R. Roach, “Acute Mountain Sickness: Pathophysiology, Prevention, and Treatment,” Prog Cardiovasc Dis, vol. 52, no. 6, pp. 467–484, May 2010, doi: 10.1016/J.PCAD.2010.02.003.
[31] T. Y. Tsai, S. H. Wang, Y. K. Lee, and Y. C. Su, “Ginkgo biloba extract for prevention of acute mountain sickness: a systematic review and meta-analysis of randomised controlled trials,” BMJ Open, vol. 8, no. 8, Aug. 2018, doi: 10.1136/BMJOPEN-2018-022005.
[32] Y. Botao et al., “Protective effect of ginkgolide B on high altitude cerebral edema of rats,” High Alt Med Biol, vol. 14, no. 1, pp. 61–64, Mar. 2013, doi: 10.1089/HAM.2012.1080.
[33] Y. Deng et al., “Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy,” Genes Dis, vol. 9, no. 1, pp. 62–79, Jan. 2022, doi: 10.1016/J.GENDIS.2021.02.009.
[34] J. R. Evans, “Ginkgo biloba extract for age-related macular degeneration,” Cochrane Database Syst Rev, vol. 2013, no. 1, Jan. 2013, doi: 10.1002/14651858.CD001775.PUB2.
[35] S. P. A. Nicolaï et al., “Ginkgo biloba for intermittent claudication,” Cochrane Database Syst Rev, vol. 2013, no. 6, p. CD006888, Jun. 2013, doi: 10.1002/14651858.CD006888.PUB3.
[36] T. Sun, X. Wang, and H. Xu, “Ginkgo Biloba extract for angina pectoris: a systematic review,” Chin J Integr Med, vol. 21, no. 7, pp. 542–550, Jul. 2015, doi: 10.1007/S11655-015-2070-0.
[37] Y. Liu et al., “Efficacy and safety of Ginkgo biloba extract in the treatment of unstable angina pectoris: A systematic review and network meta-analysis,” J Ethnopharmacol, vol. 331, Sep. 2024, doi: 10.1016/J.JEP.2024.118297.
[38] J. M. Kang and S. Lin, “Ginkgo biloba and its potential role in glaucoma,” Curr Opin Ophthalmol, vol. 29, no. 2, pp. 116–120, Mar. 2018, doi: 10.1097/ICU.0000000000000459.
[39] L. Zhou, Q. Meng, T. Qian, and Z. Yang, “Ginkgo biloba extract enhances glucose tolerance in hyperinsulinism-induced hepatic cells,” J Nat Med, vol. 65, no. 1, pp. 50–56, Jan. 2011, doi: 10.1007/S11418-010-0456-Z.
[40] B. J. Diamond and M. R. Bailey, “Ginkgo biloba: Indications, Mechanisms, and Safety,” Psychiatric Clinics of North America, vol. 36, no. 1, pp. 73–83, Mar. 2013, doi: 10.1016/J.PSC.2012.12.006.
[41] B. J. Diamond et al., “Ginkgo biloba extract: mechanisms and clinical indications,” Arch Phys Med Rehabil, vol. 81, no. 5, pp. 668–678, May 2000, doi: 10.1016/S0003-9993(00)90052-2.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Julia Mierzwińska-Mucha, Bartosz Roś, Katarzyna Siekaniec, Natalia Kuchenbeker, Adriana Dojs, Magdalena Jakubowicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 73
Number of citations: 0
